Literature DB >> 2729261

Hospital-acquired pneumonia. Attributable mortality and morbidity.

H S Leu1, D L Kaiser, M Mori, R F Woolson, R P Wenzel.   

Abstract

A total of 1,001 consecutive episodes of nosocomial pneumonia in 901 patients was identified by routine surveillance at the University of Virginia Medical Center between 1979 and 1983 (8.6 episodes/1,000 admissions). When only initial episodes were examined, 890 patients comprised the study sample. The overall case fatality rate was 30%. Stepwise logistic regression indicated that time from admission to pneumonia (p = 0.0006), age (p less than 0.0001), prior use of mechanical ventilation (p = 0.0032), and neoplastic disease (p = 0.0062) were associated with mortality. Multiple regression analysis indicated that the factors associated with increased length of hospitalization included posttracheostomy status (p = 0.0001), prior mechanical ventilation (p = 0.0001), immunosuppressive or leukopenic status (p = 0.0009), nasogastric intubation (p = 0.0003), and prior bacteremia (p = 0.0127). A sampled, individually matched cohort study (n = 74 pairs) was conducted to determine the proportion of mortality in cases that was attributable to infections (33%) and to determine excess hospital stay (seven days) among the patients with nosocomial pneumonia. Excess stay was statistically significant (p less than 0.0001), but proportional mortality was only marginally significant (p = 0.0892). Our findings suggest that nosocomial pneumonia accounts for approximately 33% of the crude mortality and contributes significantly to the economic burden associated with prolonged hospitalization.

Entities:  

Mesh:

Year:  1989        PMID: 2729261     DOI: 10.1093/oxfordjournals.aje.a115245

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  42 in total

Review 1.  Prevention of nosocomial bacterial pneumonia.

Authors:  J L Vincent
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

Review 2.  Selective decontamination of the digestive tract in intensive care.

Authors:  S J Boom; G Ramsay
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

Review 3.  Nosocomial pneumonia in the intensive care unit: mechanisms and significance.

Authors:  C A'Court; C S Garrard
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

4.  Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report.

Authors:  L A Mandell; T J Marrie; M S Niederman
Journal:  Can J Infect Dis       Date:  1993-11

5.  Regulatory effect of histamine on the barrier function of intestinal mucosal.

Authors:  Ligeng Duan; Xiaoli Chen; J W Alexander
Journal:  J Gastrointest Surg       Date:  2010-04-30       Impact factor: 3.452

Review 6.  Nosocomial pneumonia: epidemiology and infection control.

Authors:  D E Craven; K A Steger; L M Barat; R A Duncan
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 7.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

8.  Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa.

Authors:  H Grundmann; C Schneider; D Hartung; F D Daschner; T L Pitt
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization.

Authors:  A A Vegas; V M Jodra; M L García
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

10.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.